

DAFTAR PUSTAKA

1. Pandolfi F, Franza L, Carusi V, Altamura S, Andriollo G, Nucera E. Interleukin-6 in Rheumatoid Arthritis. 2020;130:1–13.
2. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. *Lancet*. 2016;388(10055):2023–38.
3. Parenti G, Tomaino SCM, Cipolletta S. The experience of living with rheumatoid arthritis: A qualitative metasynthesis. *J Clin Nurs*. 2020;29(21–22):3922–36.
4. Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. *Rheumatol Int*
5. Safiri S, Kolahi AA, Hoy D, Smith E, Bettampadi D, Mansournia MA, et al. Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017. *Ann Rheum Dis*. 2019;78(11):1463–71.
6. Boussaid S, Ayed NB, Bani M dkk. Impact of work productivity on quality of life and disease activity in ankylosing spondylitis. *J Clin Med Kazakhstan*. 2020;5(59):20–3.
7. Bąk E, Młynarska A, Marcisz C, Bobiński R, Sternal D, Młynarski R. Factors that affect the assessment of the quality of life of rheumatoid arthritis patients depending on the prevalence of frailty syndrome. *Health Qual Life Outcomes*. 2020;18(1):1–9.
8. Guerrero-López JB, Cabrera DM, del Carmen Lara-Muñoz M, García RO. Evaluation of quality of life and depression in patients with rheumatoid arthritis in a General Hospital. *Rev Colomb Reumatol (English Ed)*. 2017;24(4):199–204.
9. Center for Disease Control and Prevention. 2020 [cited 2020 Jul 27]. Available from: <https://www.cdc.gov/arthritis/basics/rheumatoid-arthritis.html>
10. Theander L, Willim M, Nilsson JÅ, Karlsson M, Åkesson KE, Jacobsson LTH,

- et al. Changes in bone mineral density over 10 years in patients with early rheumatoid arthritis. *RMD Open*. 2020;6(1).
11. Morgan H, Chan C, Clynes M, Jameson K, Cooper C, Ward K, et al. Bone Health in Rheumatoid Arthritis : What Can Studies of Bone Microarchitecture Tell Us ? (July 2020):91–9.
 12. Chen JF, Hsu CY, Yu SF, Ko CH, Chiu WC, Lai HM, et al. The impact of long-term biologics/target therapy on bone mineral density in rheumatoid arthritis: A propensity score-matched analysis. *Rheumatol (United Kingdom)*. 2020;59(9):2471–80.
 13. Hochbehr MC, Gravellese EM, Silman AJ, Smolen JS, Weinblatt ME, Weisman ME, editors. Interleukin-6 Inhibitor. In: *Rheumatology*. 2019. p. 545.
 14. Favalli EG. Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis. *Rheumatol Ther*. 2020;7(3):473–516.
 15. Makhdoom A, Rahopoto MQ, Awan S, Tahir SM, Memon S, Siddiqui KA. Bone mineral density level by dual energy X-ray absorptiometry in rheumatoid arthritis. *J Pak Med Assoc*. 2017;67(1):15–9.
 16. Adami G, Saag KG. Osteoporosis Pathophysiology, Epidemiology, and Screening in Rheumatoid Arthritis. *Curr Rheumatol Rep*. 2019;21(7).
 17. Nagy EE, Nagy-Finna C, Popoviciu H, Kovács B. Soluble biomarkers of osteoporosis and osteoarthritis, from pathway mapping to clinical trials: An update. *Clin Interv Aging*. 2020;15:501–18.
 18. England BR, Tiong BK, Bergman MJ, Curtis JR, Kazi S, Mikuls TR, et al. 2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures. *Arthritis Care Res*. 2019;71(12):1540–55.
 19. Son KM, Lee SY, Seo Y Il, Choi JE, Kim HA. Contribution of subjective Disease Activity Score 28 (DAS-28) components to the response to treatment of rheumatoid arthritis. *Clin Rheumatol*. 2017;36(6):1221–7.
 20. Ariestine, D A, Kedokteran F, Sumatera Utara U. Hubungan Kadar Interleukin-6 dengan Aktivitas Penyakit. 2012

21. Narazaki M, Tanaka T, Kishimoto T. The role and therapeutic targeting of IL-6 in rheumatoid arthritis. *Expert Rev Clin Immunol*. 2017;13(6):535–51.
22. Almoallim H, Al Saleh J, Badsha H, Ahmed HM, Habjoka S, Menassa JA, et al. A Review of the Prevalence and Unmet Needs in the Management of Rheumatoid Arthritis in Africa and the Middle East. *Rheumatol Ther*. 2021;8(1):1–16.
23. Otón T, Carmona L. The epidemiology of established rheumatoid arthritis. *Best Pract Res Clin Rheumatol*. 2019;33(5).
24. Nakajima A, Sakai R, Inoue E, Harigai M. Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan. *Int J Rheum Dis*. 2020;23(12):1676–84.
25. Indonesian Rheumatology Association. *Diagnosis & Penatalaksanaan Arthritis Reumatoid – Perhimpunan Reumatologi Indonesia*. Perhimpunan Reumatologi Indonesia. 2014. iii–26.
26. Riskesdas K. Hasil Utama Riset Kesehatan Dasar (RISKESDAS). *J Phys A Math Theor*. 2018;44(8):1–200.
27. Deane KD, Demoruelle MK, Kelmenson LB, Kuhn KA, Norris JM, Holers VM. Genetic and environmental risk factors for rheumatoid arthritis. *Best Pract Res Clin Rheumatol*. 2017;31(1):3–18.
28. P K, Liao. Classification and epidemiology of rheumatoid arthritis. In: Hochbehr MC, Gravellese EM, Silman AJ, Smolen JS, Weinblatt ME, Weisman ME, editors. *Rheumatology*. 2019. p. 750–1.
29. Pradeepkiran JA. Insights of rheumatoid arthritis risk factors and associations. *J Transl Autoimmun*. 2019;2(March):100012.
30. Scherer HU, Häupl T, Burmester GR. The etiology of rheumatoid arthritis. *J Autoimmun*. 2020;110(December 2019):102400.
31. Chauhan K, Jandu JS, Goyal A, Bansal P, Al-Dhahir MA. Rheumatoid Arthritis - StatPearls - NCBI Bookshelf. *StatPearls Publ*. 2020;(June).
32. Viatte S, Raychaudhuri S. Genetic of Rheumatoid Arthritis. In: Hochbehr MC,

- Gravellese E, Silman A, Smolen J, Weinblatt M, Weisman M, editors. Rheumatology. 2019. p. 787.
33. Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: Pathological mechanisms and modern pharmacologic therapies. *Bone Res.* 2018;6(1).
34. Suarjana IN. Artritis Reumatoid. In: Siti S, Idrus A, Sudoyo A., K MS, Setiyohardi B, Syam AF, editors. *ILMU PENYAKIT DALAM EDISI KEENAM JILID I.* 2014. p. 3131.
35. Alpízar-Rodríguez D, Pluchino N, Canny G, Gabay C, Finckh A. The role of female hormonal factors in the development of rheumatoid arthritis. *Rheumatol (United Kingdom).* 2017;56(8):1254–63.
36. Firestein GS. ETIOLOGY OF RHEUMATOID ATHRITIS. In: Firestein GS, Budd RC, Gabriel SE, Kozetzky, editors. *Firestein & Kelly's Textbook of Rheumatology.* Elsevier; 2020. p. 1182.
37. Schett G, Gravellese E. Bone erosion in rheumatoid arthritis: Mechanisms, diagnosis and treatment. *Nat Rev Rheumatol.* 2012;8(11):656–64.
38. Ho LJ, Luo SF, Lai JH. Biological effects of interleukin-6: Clinical applications in autoimmune diseases and cancers. *Biochem Pharmacol [Internet].* 2015;97(1):16–26. Available from: <http://dx.doi.org/10.1016/j.bcp.2015.06.009>
39. Schinnerling K, Aguilón JC, Catalán D, Soto L. The role of interleukin-6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis. *Clin Exp Immunol.* 2017;189(1):12–20.
40. Yoshida Y, Tanaka T. Interleukin 6 and rheumatoid arthritis. *Biomed Res Int.* 2014;2014.
41. Bartl R, Bartl C. *The osteoporosis Manual.* Springer; 2019. 35 p.
42. Index R. CTX1 is A Better Index to Evaluate The Severity of Osteoporosis then Radiographic Index. 2021;(February):41–6.
- 43.. Shetty S, Kapoor N, Bondu J, Thomas N, Paul T. Bone turnover markers: Emerging tool in the management of osteoporosis. *Indian J Endocrinol Metab.*

- 2016;20(6):846–52.
44. Eastell R, Szulc P. Use of bone turnover markers in postmenopausal osteoporosis. *Lancet Diabetes Endocrinol.* 2017;5(11):908–23.
 45. Matthew B. Greenblatt¹, Joy N. Tsai², and Marc N. Wein². Bone Turnover n Markers in the Diagnosis and Monitoring of Metabolic Bone Disease. *Clin Chem.* 2017; 63(2): 464–74.
 46. Mustofa, Sari RDP, Prabowo AY. Osteoporosis pada Wanita Peri dan Postmenopause
Osteoporosis in Pre and Postmenopausal Women. *Medula.* 2019;8:200–4.
 47. Harmer D, Falank C, Reagan MR. Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma. *Front Endocrinol (Lausanne).* 2019;10(JAN):1–15.
 48. Akil N, Isbagio H, Sumariyono S. Correlation of Serum Level of Interleukin-6 and Disease Activity with Bone-resorption Activity in Premenopausal Rheumatoid Arthritis Patients.
Indones J Rheumatol. 2013;4(1):231043.
 49. Kim JW, Suh CH. Systemic manifestations and complications in patients with rheumatoid arthritis. *J Clin Med.* 2020;9(6):1–5.
 50. Yoshiya T. Rheumatoid Arthritis (RA). 2020.
 51. D R, Brasington J, Jr J, Miner. Clinical feature of Rheumatoid Athritis. In: Hochbehrig M, Gravellese E, Silman A, Smolen J, Weinblatt M, Weisman M, editors. *Rheumatology.* 2019. p. 761.
 52. Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. *Nat Rev Dis Prim.* 2018;4:1–23.
 53. Drake DAR, Chan FT, Briski E, Bailey SA, Macisaac HJ. Extra-articular rheumatoid Athritis. 2014;73(4):112–9.
 54. Taylor PC. Update on the diagnosis and management of early rheumatoid arthritis. *Clin Med J R Coll Physicians London.* 2020;20(6):561–4.
 55. Llorente I, García-Castañeda N, Valero C, González-Álvaro I, Castañeda S. Osteoporosis in Rheumatoid Arthritis: Dangerous Liaisons. *Front Med.*

- 2020;7(November):1–11.
56. Sozen T, Ozisik L, Calik Basaran N. An overview and management of osteoporosis. *Eur J Rheumatol*. 2017;4(1):46–56.
 57. Lai EL, Huang WN, Chen HH, Hsu CY, Chen DY, Hsieh TY, et al. Ten-year fracture risk by FRAX and osteoporotic fractures in patients with systemic autoimmune diseases. *Lupus*. 2019;28(8):945–53.
 58. Fraenkel L, Bathon JM, England BR, St.Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care Res*. 2021;73(7):924–39.
 59. Hidayat R, Suryana BPP, Wijaya LK, Ariane A, Hellmi RY, Adnan E, et al. Diagnosis dan Pengelolaan Artritis Reumatoid (Rheumatoid Arthritis Diagnosis and Management) [Internet]. Perhimpunan Reumatologi Indonesia. 2021. 1–80 p.
 60. Santosa D, Hidayat R, Prasetyo M, Nugroho P. Diagnostic values of DAS-28 and DAS-28-squeeze in evaluating Rheumatoid Arthritis disease. *Indones J Rheumatol*. 2018;8(2):10–4.
 61. Sudigdo S. *Dasar–dasar Metodologi Penelitian Klinis*. Edisi 4. Jakarta. Sagung Seto. 2011.
 62. Dahlan MS. *Statistik untuk Kedokteran dan Kesehatan*. Edisi 6. Epidemiologi Indonesia. 2014.
 63. Yogaswara R, Hidayat R, Muhadi M, Rinaldi I. Korelasi antara Faktor Reumatoid dan Vascular Cell Adhesion Molecule-1 pada Pasien Artritis Reumatoid Tanpa Sindroma Metabolik. *J Penyakit Dalam Indones*. 2018;5(2):82.
 64. Kumar B, Das MP, Misra AK. A cross-sectional study of association of Rheumatoid arthritis with sero-positivity and anaemia in a tertiary care teaching hospital. *J Med Res*. 2017;3(6):280–3.
 65. Bes C. An autumn tale: Geriatric rheumatoid arthritis. *Ther Adv Musculoskelet Dis*. 2018;10(1):3–11.

66. Mudjaddid E, Puspitasari M, Setyohadi B, Dewiasty E. Hubungan Derajat Aktivitas Penyakit dengan Depresi pada Pasien Arthritis Reumatoid. *J Penyakit Dalam Indones*. 2017;4(4):194.
67. Chen L, Huang Z, Yang B, Cai B, Su Z, Wang L. Association of E26 transformation specific sequence 1 variants with rheumatoid arthritis in Chinese han population. *PLoS One*. 2015;10(8):1–11.
68. Soeroso J, Judajana FM. Hubungan antara umur, umur mulai sakit, lama sakit dengan LED, CRP, DAS28-LED di arthritis reumatoid. *Indonesian J Clin Pathol Lab Med*. 2014; 20(2): 85-92.
69. Lau CS, Chia F, Dans L, Harrison A, Hsieh TY, Jain R, et al. 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. *Int J Rheum Dis*. 2019;22(3):357–75.
70. Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis*. 2020;79(6):S685–99.
71. Abdel Moneim H. Helala, Enas M. Shahinea, Marwa M. Hassana, Doaa I. Hashadb, Riham Abdel Moneima. Fatigue in rheumatoid arthritis and its relation to interleukin-6 serum level. *The Egyptian Rheumatologist* 2012; 34(4):153-157.
72. Oky P, Tania A, Simamora D, Dyah Parmasari W, Rahmawati F, Biomedik B, et al. Kadar Interleukin 6 (Il-6) Sebagai Indikator Progresivitas Penyakit Reumatoid Arthritis 6(Ra). *Ilm Kedokt*. 2014;3:40–7.
73. Teitsma XM, Marijnissen AKA, Bijlsma JWJ, Lafeber FPJ, Jacobs JWG. Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: A meta-analysis of efficacy and safety reported in

- randomized controlled trials. *Arthritis Res Ther.* 2016;18(1).
74. Handono K, Putra SB, Sulistyorini S. Korelasi Kadar CRP, TNF- α dan Densitas massa tulang dengan Carboxyterminal Crosslinked Telopeptide of Type 1 Collagen di Penderita Artritis Reumatoid. *Indones J Clin Pathol Med Lab.* 2012;18(2):72–8
75. Dimitri V, Kedokteran F, Andalas U. Perbedaan Kadar CTX-1, TNF- α dan IL-1 Serum pada Pasien Artritis Reumatoid berdasarkan derajat Aktivitas Penyakit. 2020
76. Liu D, Guo M, Yun M, Jiao Y, Zhang J, Luo Y, et al. Diagnostic value of serum and joint fluid anti-CCP (citrulline-containing peptide) antibody for rheumatoid arthritis and its relationship with other inflammatory indicators. *Sci Res Essays.* 2011;6(12):2465–9.
77. Chen YM, Chen HH, Huang WN, Liao TL, Chen JP, Chao WC, et al. Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis. *PLoS One.* 2017;12(11):1–13.
78. Hashimoto J, Garnero P, Van Der Heijde D, Miyasaka N, Yamamoto K, Kawai S, et al. Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: Data from the SAMURAI study. *Mod Rheumatol.* 2011;21(1):10–5.
79. Chung SJ, Kwon YJ, Park MC, Park YB, Lee SK. The correlation between increased serum concentrations of interleukin-6 family cytokines and disease activity in rheumatoid arthritis patients. *Yonsei Med J.* 2011;52(1):113–20.
80. Abdel Meguid MH, Hamad YH, Swilam RS, Barakat MS. Relation of interleukin-6 in rheumatoid arthritis patients to systemic bone loss and structural bone damage. *Rheumatol Int.* 2013;33(3):697–703.